Axonics, Inc. (AXNX) Stock

About Axonics, Inc.

Axonics, Inc. is a medical device firm that focuses on developing and bringing to market sacral neuromodulation (SNM) solutions. These advanced SNM systems are designed to address a range of medical conditions, such as overactive bladder (including urinary urge incontinence and frequent urges to urinate), alongside fecal incontinence and non-obstructive urinary retention. The company's flagship rechargeable SNM System, known as r-SNM, operates by delivering gentle electrical impulses to specific sacral nerves, aiming to restore regular communication between the brain and the bladder or bowel, thereby lessening the symptoms of their dysfunction. Beyond its SNM portfolio, Axonics also provides Bulkamid, a urethral bulking agent for managing stress urinary incontinence in women. The firm distributes its offerings both through its dedicated sales team and a network of distributors across the United States, the United Kingdom, Germany, the Netherlands, the Nordic region, and other international markets. Established in 2012 and headquartered in Irvine, California, the company was initially known as Axonics Modulation Technologies, Inc., before officially changing its name to Axonics, Inc. in March 2021.

Axonics, Inc. is headquartered in US.

Axonics, Inc. (AXNX) stock trades at $70.98 with a market capitalization of $3.63B. The stock is valued at a price-to-earnings (P/E) ratio of -591.50, price-to-book of 5.46, price-to-sales of 9.90. Over the past 52 weeks the stock has ranged between $70.98 and $70.98, and currently trades at its 52-week high.

On profitability, Axonics, Inc. generates a return on equity (ROE) of -1.01%, return on capital employed of -3.87%, an operating margin of -7.11%, a net profit margin of -1.66%.

Official website: www.axonics.com